Manfred Kaufmann
Response-guided neoadjuvant chemotherapy for breast cancer
von Minckwitz G, Mehta K, Zahm D, Untch M, Schneeweiss A, Paepke S, Kümmel S, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Eidtmann H, Denkert C, Costa S, Blohmer J, Loibl S. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31:3623-30.
Sep 3, 2013Response-guided neoadjuvant chemotherapy for breast cancer
Sep 3, 2013J Clin Oncol 2013; 31:3623-30
von Minckwitz Gunter, Mehta Keyur, Zahm Dirk Michael, Untch Michael, Schneeweiss Andreas, Paepke Stefan, Kümmel Sherko, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eiermann Wolfgang, Eidtmann Holger, Denkert Carsten, Costa Serban Dan, Blohmer Jens Uwe, Loibl Sibylle
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
von Minckwitz G, Mehta K, Nekljudova V, Denkert C, Konecny G, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Eiermann W, Gerber B, Fasching P, Eidtmann H, Costa S, Blohmer J, Untch M, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796-804.
Apr 16, 2012Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
Apr 16, 2012J Clin Oncol 2012; 30:1796-804
von Minckwitz Gunter, Mehta Keyur, Nekljudova Valentina, Denkert Carsten, Konecny Gottfried E, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Eiermann Wolfgang, Gerber Bernd, Fasching Peter A, Eidtmann Holger, Costa Serban D, Blohmer Jens-Uwe, Untch Michael, Loibl Sibylle
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Untch M, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Hanusch C, Tesch H, Kreienberg R, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J, Hilfrich J, Strumberg D, Fasching P, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13:135-44.
Jan 17, 2012Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Jan 17, 2012Lancet Oncol 2012; 13:135-44
Untch Michael, Gerber Bernd, Rezai Mahdi, Jackisch Christian, Huober Jens, Kühn Thorsten, Nekljudova Valentina, von Minckwitz Gunter, German Breast Group (GBG), Hanusch Claus, Tesch Hans, Kreienberg Rolf, Loibl Sibylle, Bischoff Joachim, Eidtmann Holger, Kaufmann Manfred, Blohmer Jens-Uwe, Hilfrich Jörn, Strumberg Dirk, Fasching Peter A, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
von Minckwitz G, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jackisch C, Hilfrich J, Mehta K, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J, Costa S, Jüni P. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2010; 125:145-56.
Nov 3, 2010Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
Nov 3, 2010Breast Cancer Res Treat 2010; 125:145-56
von Minckwitz Gunter, Gerber Bernd, du Bois Andreas, Huober Jens, Hanusch Claus, Konecny Gottfried, Fett Werner, Stickeler Elmar, Harbeck Nadia, Müller Volkmar, Jackisch Christian, Hilfrich Jörn, Mehta Keyur, Untch Michael, Nüesch Eveline, Loibl Sibylle, Kaufmann Manfred, Kümmel Sherko, Fasching Peter A, Eiermann Wolfgang, Blohmer Jens-Uwe, Costa Serban Dan, Jüni Peter
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
von Minckwitz G, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Untch M. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28:2015-23.
Mar 22, 2010Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
Mar 22, 2010J Clin Oncol 2010; 28:2015-23
von Minckwitz Gunter, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, Untch Michael
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Untch M, Kühn T, du Bois A, Blohmer J, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Hanusch C, Gerber B, Rezai M, Loibl S, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, von Minckwitz G. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28:2024-31.
Mar 22, 2010Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Mar 22, 2010J Clin Oncol 2010; 28:2024-31
Untch Michael, Kühn Thorsten, du Bois Andreas, Blohmer Jens-Uwe, Thomssen Christoph, Dan Costa Serban, Jackisch Christian, Kaufmann Manfred, Mehta Keyur, Hanusch Claus, Gerber Bernd, Rezai Mahdi, Loibl Sibylle, Fasching Peter A, Huober Jens, Tesch Hans, Bauerfeind Ingo, Hilfrich Jörn, Eidtmann Holger, von Minckwitz Gunter
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
Costa S, Tesch H, Gerber B, Baumann K, Thomssen C, Breitbach G, Ibishi S, Jackisch C, Mehta K, Weiss E, Ataseven B, Loibl S, Kaufmann M, Zahm D, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer J, von Minckwitz G. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:83-91.
Jan 1, 2010Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data
Jan 1, 2010Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:83-91
Costa Serban Dan, Tesch Hans, Gerber Bernd, Baumann Klaus H, Thomssen Christoph, Breitbach Georg Peter, Ibishi Shaip, Jackisch Christian, Mehta Keyur, Weiss Erich, Ataseven Beyhan, Loibl Sibylle, Kaufmann Manfred, Zahm Dirk-Michael, Hilfrich Jörn, Huober Jens, Eidtmann Holger, du Bois Andreas, Blohmer Jens-Uwe, von Minckwitz Gunter
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
von Minckwitz G, Kaufmann M, Mehta K, Loibl S, Jackisch C, Costa S, Huober J, Gerber B, Hilfrich J, Eidtmann H, Hanusch C, Vogel P, Kümmel S, German Breast Group. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. Journal of the National Cancer Institute 2008; 100:542-51.
Apr 16, 2008Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial
Apr 16, 2008Journal of the National Cancer Institute 2008; 100:542-51
von Minckwitz Gunter, Kaufmann Manfred, Mehta Keyur, Loibl Sibylle, Jackisch Christian, Costa Serban Dan, Huober Jens, Gerber Bernd, Hilfrich Jörn, Eidtmann Holger, Hanusch Claus, Vogel Petra, Kümmel Sherko, German Breast Group
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study
von Minckwitz G, Kaufmann M, Mehta K, Loibl S, Jackisch C, Costa S, Huober J, Gerber B, Hilfrich J, Eidtmann H, Hanusch C, Vogel P, Kümmel S, German Breast Group. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. Journal of the National Cancer Institute 2008; 100:552-62.
Apr 16, 2008Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study
Apr 16, 2008Journal of the National Cancer Institute 2008; 100:552-62
von Minckwitz Gunter, Kaufmann Manfred, Mehta Keyur, Loibl Sibylle, Jackisch Christian, Costa Serban Dan, Huober Jens, Gerber Bernd, Hilfrich Jörn, Eidtmann Holger, Hanusch Claus, Vogel Petra, Kümmel Sherko, German Breast Group